E N D
1. (Neo-)adjuvant treatment of gastric cancer: radio-chemo-therapy? Tom Boterberg
Department of Radiation Oncology
University Hospital Gent
2. Criteria for adjuvant therapy Complete resection, no metastases
High risk of relapse due to (occult) residual disease
Treatment should increase disease-free period and/or cure rate
Acceptable toxicity
4. Postoperative chemotherapy?
5. Any role for adjuvant R(CT)?
6. Is radiotherapy used optimally?
7. What is the target volume?
8. Anatomical challenges
9. Modern radiotherapy
10. Adjuvant radiochemotherapy I Macdonald et al., NEJM 2001
556 pts gastric carcinoma + GE junction
Surgery versus surgery + RCT
5-FU > 45 Gy + 5-FU > 5-FU
OS: 27 months vs 36 months
Time to relapse: 19 vs 30 months
Major problem: extent of surgery
11. Intergroup Study INT-0116Results
12. Survival data
13. Adjuvant radiochemotherapy II Kim et al., IJROBP 2005
990 pts D2-resected gastric cancer
Observational study (not randomized)
5-FU > 45 Gy + 5-FU > 5-FU
OS: 63 vs 95 months
Relapse-free survival: 53 vs 76 months
Selected from 3447 pts (no stage I)
14. Survival according to stage
15. Survival data
16. Is there a role for radiotherapy in gastric cancer? Probably there is, but...
17. With care and consideration How to select patients (II-III?)
Use modern radiotherapy techniques
Addition of chemotherapy may make the difference
What is the optimal timing?
18. Preoperative radiochemotherapy
19. Future role for radio(chemo)therapy? Postoperative radiochemotherapy: a new standard? Is the chemotherapy satisfactory?
Combination with recent biologicals with potential radiosensitising effect?
What about docetaxel, CPT-11, oxaliplatin? Preliminary data in advanced disease
Biological or immunological molecules?
Timing of radio-chemotherapy?
20. MAGIC Trial ASCO 2005 UK 1994-2002
503 patients
Resectable gastric (74%), oesophago-gastric junction (11%) or distal oesophagus (15%) adenocarcinoma
Epirubicin, cisplatin, 5-FU (ECF)
Surg. vs 3 x ECF + Surgery + 3 x ECF